Stable liquid vigabatrin pharmaceutical composition for oral dosage
US12016857B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 2, 2023 |
| Grant date | Jun 25, 2024 |
| Priority date | — |
| Expiry date | May 2, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.